Allen P Anandarajah

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications
    Allen P Anandarajah
    Department of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Cell Biochem 97:226-32. 2006
  2. ncbi The diagnosis and treatment of early psoriatic arthritis
    Allen P Anandarajah
    Clinical Immunology Research Center, Allergy, Immunology and Rheumatology Research Division, University of Rochester Medical Center, 601 Elmwood Avenue, P O Box 695, Rochester, NY 14642, USA
    Nat Rev Rheumatol 5:634-41. 2009
  3. ncbi Role of RANKL in bone diseases
    Allen P Anandarajah
    Division of Allergy, University of Rochester Medical Center, Rochester, NY 14642, USA
    Trends Endocrinol Metab 20:88-94. 2009
  4. ncbi Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies
    Allen P Anandarajah
    Clinical Immunology Research Center, Rochester, New York 14642, USA
    Adv Exp Med Biol 649:85-99. 2009
  5. ncbi Etanercept in psoriatic arthritis
    Allen P Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Expert Opin Biol Ther 3:169-77. 2003
  6. ncbi Pathogenesis of psoriatic arthritis
    Allen P Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Curr Opin Rheumatol 16:338-43. 2004
  7. ncbi Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents
    Allen P Anandarajah
    Department of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    Postgrad Med 116:31-6, 39-40. 2004

Detail Information

Publications7

  1. ncbi Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications
    Allen P Anandarajah
    Department of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Cell Biochem 97:226-32. 2006
    ..Here, we review the etiology of inflammatory bone loss, the RANK/RANK-ligand/OPG pathway, and the clinical development of anti-RANK-ligand therapy...
  2. ncbi The diagnosis and treatment of early psoriatic arthritis
    Allen P Anandarajah
    Clinical Immunology Research Center, Allergy, Immunology and Rheumatology Research Division, University of Rochester Medical Center, 601 Elmwood Avenue, P O Box 695, Rochester, NY 14642, USA
    Nat Rev Rheumatol 5:634-41. 2009
    ..The extent of disease and the presence of comorbidities should be used to guide treatment decisions and to minimize adverse events...
  3. ncbi Role of RANKL in bone diseases
    Allen P Anandarajah
    Division of Allergy, University of Rochester Medical Center, Rochester, NY 14642, USA
    Trends Endocrinol Metab 20:88-94. 2009
    ..Here, I provide an overview of recent studies that highlight the key role of RANKL in the pathophysiology of several bone diseases and discuss the novel therapeutic approaches afforded by the modulation of RANKL...
  4. ncbi Bone loss in the spondyloarthropathies: role of osteoclast, RANKL, RANK and OPG in the spondyloarthropathies
    Allen P Anandarajah
    Clinical Immunology Research Center, Rochester, New York 14642, USA
    Adv Exp Med Biol 649:85-99. 2009
    ....
  5. ncbi Etanercept in psoriatic arthritis
    Allen P Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Expert Opin Biol Ther 3:169-77. 2003
    ..In summary, etanercept is a safe and effective agent for the treatment of PsA and represents a major advance in the therapy of this potentially crippling disease...
  6. ncbi Pathogenesis of psoriatic arthritis
    Allen P Anandarajah
    Allergy, Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, New York 14642, USA
    Curr Opin Rheumatol 16:338-43. 2004
    ..Histopathologic data and results from clinical trials highlight the predominance of TNF-mediated inflammation in psoriatic joint tissues...
  7. ncbi Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents
    Allen P Anandarajah
    Department of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, New York 14642, USA
    Postgrad Med 116:31-6, 39-40. 2004
    ..Here, Drs Anandarajah and Ritchlin explore the effectiveness of conventional therapies as well as biologic agents that are currently available or under development...